Physicians Recommend Lung Monitoring for T-DXd Patients
New clinical guidance calls for structured CT screening to manage interstitial lung disease risks in breast cancer care.
Updated on Oct. 27, 2026 in Asthma
Live Poll
Do you trust that current medical guidelines for drug safety provide enough protection for patients?
Medical experts recommend structured interstitial lung disease monitoring for breast cancer patients receiving T-DXd treatment. This approach uses baseline and follow-up CT imaging to identify pulmonary changes throughout the course of care.
Why it matters
Coordinated monitoring is essential to distinguish between drug-induced lung disease and pulmonary changes caused by radiation therapy. This allows for the safer integration of T-DXd into established breast cancer treatment regimens.
The DESTINY-Breast05 clinical trial utilized a protocol requiring baseline and regular follow-up CT imaging to track pulmonary health. Researchers are still evaluating how these findings differentiate from treatment-related outcomes.
The players
DESTINY-Breast05
This is a clinical trial focused on evaluating treatment outcomes for patients with breast cancer.
The details
Medical oncology, radiology, and radiation oncology teams must collaborate to assess imaging results, as radiation therapy frequently mimics drug-induced disease. Differentiating between asymptomatic radiographic patterns and symptomatic conditions remains central to patient safety protocols.
Timeline
Ongoing monitoring is required for patients throughout the duration of T-DXd breast cancer treatment.
The Big Picture
This approach aligns with the diagnostic standards set by the DESTINY-Breast05 clinical trial. It marks a shift toward more rigorous, cross-disciplinary imaging protocols to manage potential treatment side effects.
Patients undergoing breast cancer treatment may face more frequent imaging appointments to track pulmonary changes. These diagnostic steps are designed to minimize risks while maintaining the efficacy of T-DXd regimens.
The takeaway
Patients should communicate clearly with their oncology and radiology teams to understand their specific monitoring schedule. Early detection of asymptomatic changes can help medical providers make more informed decisions regarding treatment continuation.
Further reading
Learn more about managing respiratory health conditions in our Asthma section.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that current medical guidelines for drug safety provide enough protection for patients?
